Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10881 - 10888 of 11616 results
Another Social Media Battleground: Employee LinkedIn Accounts - "It's Mine" - "No It's Not"
October 15, 2012| Blog| Viewpoint
Centers for Medicare & Medicaid Services (CMS) Falls Short in Response to Healthcare Data Breaches
October 13, 2012| Blog| Viewpoint
New Star Ratings for Medicare Advantage and Prescription Drug Plans Go Live
October 12, 2012| Blog| Viewpoint
Corporate Integrity Agreements: OIG Provides Glimpse of the Future
October 11, 2012| Blog| Viewpoint
HHS OIG Identifies Shortcomings in CMS’s Response to Data Breaches and Medical Identity Theft
October 11, 2012| Blog| Viewpoint
Pattern Designs on US Navy Uniforms and Fabric Are Non-Functional Protected Trademarks
October 9, 2012| Blog| Viewpoint
Fiscal Year 2013 Work Plan Highlights OIG’s Medicare Parts C and D Priorities
October 9, 2012| Blog| Viewpoint
New California Legislation Prohibits Employers from Requiring Access to Social Media Accounts of Employees
October 9, 2012| Blog| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.